A proteolysis targeting chimera (PROTAC) [2] is a molecule that can remove specific unwanted proteins. Rather than acting as a conventional enzyme inhibitor , a PROTAC works by …

Jan 18, 2022 · Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to tackle disease-causing proteins that have historically been highly challenging to …

Mar 12, 2020 · Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules with three chemical elements: a ligand binding to a target protein, a ligand binding to E3 …

Dec 22, 2022 · PROTAC technology has been developed for nearly 20 years, and some molecules have entered clinical trials, which reveals the huge therapeutic potential of …

Currently, a new technology termed PROTAC, proteolysis targeting chimera, has been developed for inducing the protein degradation by a targeting molecule. This technology takes advantage …

Mar 12, 2020 · PROTACs opened a new chapter for novel drug development. However, any new technology will face many new problems and challenges. Perspectives on the potential …

Apr 4, 2022 · In recent years, PROteolysis TArgeting Chimeras (PROTAC) technology has emerged as one of the most promising approaches to remove specific disease-associated …

Oct 5, 2024 · This review provides a comprehensive overview of the advancements made by PROTAC technology in drug development and drug target discovery, while also systematically …

Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules with three chemical elements: a ligand binding to a target protein, a ligand binding to E3 ubiquitin ligase, …

Oct 5, 2024 · This review provides a comprehensive overview of the advancements made by PROTAC technology in drug development and drug target discovery, while also systematically …